PerkinElmer Receives FDA Clearance for World's First Tandem Mass Spectrometry Newborn Screening System.

BOSTON -- PerkinElmer, Inc. (NYSE: PKI):

--Kit Screens for Metabolic Disorders; Enables Early Detection and Intervention

--Analyzes More Than 40 Disease Markers with a Single Blood Sample

PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research and analytical solutions, today announced that it has received clearance from the U.S. Food and Drug Administration for its NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit. PerkinElmer now has the world's first kit cleared by the FDA for use in the global standardization of Metabolic Screening with Tandem Mass Spectrometry.

Newborn screening for metabolic disorders has become one of the most widely accepted procedures in preventative pediatrics. From a single newborn heel-stick blood sample, PerkinElmer genetic screening tools are used to screen for a variety of metabolic disorders. Early detection increases treatment and management options, leading to an improved quality of life.

"FDA clearance of this kit means there is a powerful new tool available to protect the health of newborns," said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences. "By testing for multiple disorders from a single sample, this technology provides a timely and very cost-effective approach to identifying newborns at risk for life-threatening metabolic disorders. Early intervention and treatment can improve health, lower healthcare costs and save lives."

The FDA cleared the test based on an epidemiological study of blood samples analyzed using both current testing methods and the NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit.

PerkinElmer is the world's leading supplier to newborn screening laboratories. Every baby screened in the United States today is tested using PerkinElmer's genetic screening tools. Approximately 20 percent of the world's infants currently receive some type of newborn screening, and approximately 65 percent of those are screened using PerkinElmer genetic screening products.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, all projections of future financial results, are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including, without limitation, economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries, risks related to our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, cyclical downturns continuing to affect several of the industries into which we sell our products, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory compliance, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q, each on file with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.